Free Trial
ASX:MSB

Mesoblast (MSB) Stock Price, News & Analysis

Mesoblast logo

About Mesoblast Stock (ASX:MSB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10.19 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
2.58%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive MSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MSB Stock News Headlines

Mesoblast Finally Gets Its Approval In GVHD: Where Now?
How to piss off your liberal friends… and profit from it
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
3 ASX 300 shares smashing new highs while the market dives
See More Headlines

MSB Stock Analysis - Frequently Asked Questions

Mesoblast Limited (ASX:MSB) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) earnings per share (EPS) for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Fortescue (FMG), MicroStrategy (MSTR), Aus Tin Mining (ANW), OceanaGold (OGC), Piedmont Lithium (PLL) and Alliance Resource Partners (ARLP).

Company Calendar

Last Earnings
2/21/2019
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
CIK
N/A
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-87,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.90 million
Book Value
A$0.42 per share

Miscellaneous

Outstanding Shares
1,140,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
2.38
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (ASX:MSB) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners